Related Experiment Video
Updated: Apr 26, 2026
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
Targeted antiosteosarcoma methotrexate-bisphosphonate conjugate induces apoptosis of osteosarcoma cells in vitro
1Orthopedic Department, Xuzhou No. 1 Hospital, Xuzhou, China. tomzeng5@163.com.
Objectives:
To investigate the effect of targeted antiosteosarcoma methotrexate-bisphosphonate conjugate on growth inhibition and apoptosis in human osteosarcoma MG-63 cells.
Materials And Methods:
MG-63 cells were treated with various concentrations of methotrexate-bisphosphonate conjugate and apoptosis was monitored via an MTT assay, cell morphology, TUNEL assay and flow cytometry analysis.
Results:
The survival rate of MG-63 cells treated for 24 to 96 hours with 2000 mg/ml or more of methotrexate-bisphosphonate conjugate decreased significantly. Cells treated with conjugate showed typical apoptotic features using inverted phase contrast microscopy and fluorescence staining, and the majority of cells demonstrated a positive result in the TUNEL assay. Karyopyknosis and crescent aggregation of chromatin were observed in conjugate-treated cells by electron microscopy. Flow cytometry of MG-63 cells treated with methotrexate-bisphosphonate conjugate showed a time and dose-dependent increase in apoptosis (p < 0.05).
Conclusions:
A targeted antiosteosarcoma methotrexate-bisphosphonate conjugate induces apoptosis in human osteosarcoma MG-63 cells. This new conjugate is a valuable experimental tool for the therapy of osteosarcoma.
Insights
A novel methotrexate-bisphosphonate conjugate effectively inhibits osteosarcoma cell growth and induces apoptosis in human MG-63 cells. This targeted conjugate shows promise as an experimental therapeutic agent for osteosarcoma.
Area of Science:
- Oncology
- Pharmacology
- Cell Biology
Background:
- Osteosarcoma is a primary bone malignancy with limited treatment options.
- Targeted drug delivery aims to improve therapeutic efficacy and reduce systemic toxicity.
Purpose of the Study:
- To evaluate the anti-cancer effects of a novel methotrexate-bisphosphonate conjugate.
- To assess the conjugate's ability to induce apoptosis in human osteosarcoma MG-63 cells.
Main Methods:
- MG-63 cells were treated with varying concentrations of the methotrexate-bisphosphonate conjugate.
- Apoptosis was assessed using MTT assay, cell morphology, TUNEL assay, and flow cytometry.
- Electron microscopy was employed to observe cellular ultrastructure changes.
Main Results:
- The conjugate significantly reduced MG-63 cell survival in a time- and dose-dependent manner.
- Apoptotic features, including karyopyknosis and chromatin aggregation, were observed.
- Flow cytometry confirmed a significant increase in apoptosis (p < 0.05) in treated cells.
Conclusions:
- The targeted methotrexate-bisphosphonate conjugate effectively induces apoptosis in human osteosarcoma cells.
- This conjugate represents a promising experimental tool for osteosarcoma therapy.
More Related Videos
11:15A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells
Published on: May 6, 2018
12:18LINE-1 Methylation Analysis in Mesenchymal Stem Cells Treated with Osteosarcoma-Derived Extracellular Vesicles
Published on: February 1, 2020
